ProfileGDS5678 / 1423145_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 75% 86% 26% 26% 23% 23% 22% 25% 25% 25% 26% 39% 25% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5803124
GSM967853U87-EV human glioblastoma xenograft - Control 25.0311275
GSM967854U87-EV human glioblastoma xenograft - Control 36.5960186
GSM967855U87-EV human glioblastoma xenograft - Control 42.5418926
GSM967856U87-EV human glioblastoma xenograft - Control 52.5565926
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6014123
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5633123
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.504822
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5589425
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5752225
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5740325
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5794926
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9007439
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5691925